Candel Therapeutics (CADL)
(Delayed Data from NSDQ)
$6.75 USD
+0.37 (5.80%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $6.74 -0.01 (-0.15%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
CADL 6.75 +0.37(5.80%)
Will CADL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CADL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CADL
Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why
Candel (CADL) Reports Upbeat Data From Lung Cancer Study
CADL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study
Candel (CADL) Rises on FDA's Fast Track Status for CAN-2409
Other News for CADL
CADL Stock Earnings: Candel Therapeutics Reported Results for Q2 2024
Candel Therapeutics GAAP EPS of -$0.74
Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Candel Therapeutics reports Q2 EPS (74c) vs (33c) last year
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing (CORRECTED)